A Study of Barzolvolimab in Patients With Atopic Dermatitis
← catalyst calendarSponsored by Celldex Therapeutics (industry) · CLDX — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
131actual
Sites
33
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-18 | actual | When the study began enrolling |
| Primary completion | 2026-05-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Biological: Barzolvolimab
- Drug: Matching placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from Baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16
measured From Day 1 (first dose) to Day 113 (week 16)
Permalink · CLDX's whole pipeline · Catalyst calendar · Every registered study · What changed